29 Papers
70 Citations
K. Beal is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Radiosurgery & Medicine. The author has an hindex of 8, co-authored 29 publications.
Chat about Author
Papers
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
Fabio M. Iwamoto,Lauren E. Abrey,K. Beal,Philip H. Gutin,Marc K. Rosenblum,Victor E. Reuter,Lisa M. DeAngelis,Andrew B. Lassman +7 more
TL;DR: Iwamoto et al. as discussed by the authors reported on patterns of relapse and survival in patients treated with bevacizumab (BEV) for recurrent glioblastoma (GBM).
Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence
TL;DR: Wang et al. as discussed by the authors evaluated the utility of DWI and DSC perfusion imaging alone and in combination to differentiate treatment-related effects and recurrent high-grade gliomas.
178
Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.
Andrew L. Lin,Andrew L. Lin,Philip Jonsson,Viviane Tabar,Viviane Tabar,T. Jonathan Yang,John J. Cuaron,K. Beal,Marc Cohen,Marc Cohen,Michael A. Postow,Michael A. Postow,Marc Rosenblum,Marc Rosenblum,Jinru Shia,Jinru Shia,Lisa M. DeAngelis,Lisa M. DeAngelis,Barry S. Taylor,Robert J. Young,Robert J. Young,Eliza B Geer +21 more
TL;DR: Combination treatment with ipilimumab and nivolumab may be an effective treatment in pituitary carcinoma and identify the development of therapy-induced somatic hypermutation, which may be associated with treatment response to immunotherapy.
119
Study of quadrant high-dose intraoperative radiation therapy for early-stage breast cancer.
TL;DR: The aim of this study was to determine the feasibility of using quadrant high‐dose intraoperative radiation therapy (IORT) for the treatment of early‐stage breast cancer.
48
Phase II Study of Bevacizumab (BEV), Temozolomide (TMZ) and Hypofractionated Stereotactic Radiotherapy (HFSRT) for Newly Diagnosed Glioblastoma (GBM)
K. Beal,Antonio Omuro,Sasan Karimi,Denise D. Correa,Timothy A. Chan,Lisa M. DeAngelis,Yoshiya Yamada,Lauren E. Abrey,P.H. Gutin +8 more
TL;DR: Despite a more aggressive RT schedule, the regimen was safe and more convenient for pts (shorter treatment, high response rates, preserved cognitive function throughout and following RT).
14